Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HIMS
- Rev/Share 8.038
- Book/Share 2.4743
- PB 26.7473
- Debt/Equity 0.1154
- CurrentRatio 1.5942
- ROIC 0.2452
- MktCap 14258745720.0
- FreeCF/Share 1.0821
- PFCF 59.3578
- PE 89.3656
- Debt/Assets 0.0711
- DivYield 0
- ROE 0.3597
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | HIMS | Needham | Buy | Hold | -- | -- | June 23, 2025 |
| Reiterated | HIMS | Needham | -- | Buy | $61 | $65 | June 4, 2025 |
| Downgrade | HIMS | TD Cowen | Buy | Hold | -- | $30 | April 29, 2025 |
| Downgrade | HIMS | Morgan Stanley | Overweight | Equal Weight | $42 | $60 | Feb. 18, 2025 |
| Downgrade | HIMS | Citigroup | Neutral | Sell | $24 | $25 | Jan. 10, 2025 |
| Initiation | HIMS | BTIG Research | -- | Buy | -- | $35 | Jan. 7, 2025 |
| Initiation | HIMS | Morgan Stanley | -- | Overweight | -- | $42 | Dec. 17, 2024 |
| Initiation | HIMS | Needham | -- | Buy | -- | $24 | Aug. 22, 2024 |
News
Hims & Hers Health: Focus On The Future, Not GLP-1s
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health, Inc. reported strong growth, with Q4 sales up $80 million sequentially, yet HIMS stock fell due to GLP-1 business confusion. The online health and wellness platform guided to $2.3 billion in 2025 revenues and $300 million in adjusted EBITDA despite the FDA ending GLP-1 shortages. Hims' non-GLP-1 sales grew 43% to $1.2 billion, showing its business isn't reliant on GLP-1 sales.
Read More
HIMS Stock Craters – Is It a Buying Opportunity?
Published: February 25, 2025 by: 24/7 Wall Street
Sentiment: Negative
Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer healthcare platform said it couldn't guarantee it would be able to continue selling its knockoff versions of weight-loss drugs Ozempic and Wegovy.
Read More
Hims Stock Crashed After Earnings. What Went Wrong?
Published: February 25, 2025 by: The Motley Fool
Sentiment: Negative
In this video, I will go over the fourth-quarter earnings report from Hims & Hers (HIMS -27.60%) and explain why the stock crashed on Tuesday. Watch the short video to learn more, consider subscribing, and click the special offer link below.
Read More
Hims & Hers Stock Crashed 26% Today. Here's What You Need to Know
Published: February 25, 2025 by: The Motley Fool
Sentiment: Negative
Hims & Hers (HIMS -27.66%) continues to grow at an astounding rate as the company grows subscribers and revenue per subscriber. But Hims & Hers stock is falling after earnings because investors are concerned about the future of GLP-1s.
Read More
Hims & Hers shares plunge 28% on concerns over weight loss business, margins
Published: February 25, 2025 by: CNBC
Sentiment: Negative
Hims & Hers shares fell on Tuesday, a day after the company released fourth-quarter results that disappointed on gross margin and outlined changes to its weight loss business. The company reported $481 million in revenue for the quarter, up 95% from $246.6 million during the same period last year.
Read More
Hims & Hers CFO talks Q4 earnings
Published: February 25, 2025 by: Yahoo Finance
Sentiment: Neutral
Hims & Hers Health (HIMS) stock is dropping in extended hours upon the telehealth company's fourth quarter earnings release, topping revenue ($481.14 million vs. forecasts of $470.39 million) and total subscribers estimates (2.23 million vs.
Read More
Bitcoin Concerns, SPX Upside to "$6030" & HIMS Sinks
Published: February 25, 2025 by: Schwab Network
Sentiment: Negative
As Bitcoin (/BTC) falls to 3-month lows, Kevin Green points to fundamental factors that are weighing on its price activity. He says the technical setup indicates possible selling pressure remains for popular crypto asset.
Read More
Hims & Hers Earnings: Very Strong Business, In A Very Crowded Trade
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Neutral
Hims & Hers experienced a sell-off due to profit-taking and weaker-than-expected EBITDA margins, despite strong revenue growth. The company is projected to generate over $2 billion in revenues and $350 million in free cash flow in 2025, with no debt. While EBITDA margins have fluctuated, free cash flow remains strong, making the stock attractive at 26x forward free cash flow.
Read More
Hims & Hers: Why This Q4 Earnings Dip Is A Buying Opportunity
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers stock fell ~19% post-Q4 earnings despite revenue beating expectations and EPS aligning with estimates, attributed to gross margin concerns and potential dependency on GLP-1 for future growth. The company's growth remains strong, with a 95% YoY revenue increase, an expanding subscriber base, and higher revenue per subscriber, indicating robust market capture and customer loyalty. Future potential is promising with new service additions, a vast addressable market, and strategic diversification, mitigating risks from competition and regulatory changes.
Read More
Hims & Hers: Post Earnings Drop Is Very Welcomed
Published: February 24, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers reported a double beat with Q4 revenue at $481M, a 95% YoY improvement, but faced an 18% stock drop after hours. Despite margin contraction due to new weight loss offerings, adjusted EBITDA increased 163% YoY, highlighting long-term growth potential. Management's goal of 10 million subscribers in 5–6 years, with AI integration and Trybe Labs acquisition, presents a bullish opportunity.
Read More
Compared to Estimates, Hims & Hers Health (HIMS) Q4 Earnings: A Look at Key Metrics
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Hims & Hers Health (HIMS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Hims & Hers warns its supply of compounded weight loss drugs could be 'constrained'
Published: February 24, 2025 by: Reuters
Sentiment: Negative
Hims & Hers said the U.S. FDA's decision that the shortage of Novo Nordisk's weight-loss and diabetes drugs had been resolved could constrain the telehealth firm's ability to continue providing access to compounded versions of the drugs on its platform once current inventory has been sold.
Read More
Hims & Hers offers upbeat forecast, but stock slides after hours
Published: February 24, 2025 by: Market Watch
Sentiment: Neutral
Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street's expectations, but shares fell hard in after-hours trading, in an echo of Friday's sell-off amid concerns about the fate of its Ozempic alternatives.
Read More
Hims & Hers shares tumble 18% as margin miss adds to concerns about GLP-1 business
Published: February 24, 2025 by: CNBC
Sentiment: Negative
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended trading. The company's margin of
Read More
Here's Why Hims & Hers Health, Inc. (HIMS) is a Strong Momentum Stock
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Hims & Hers Declines - How The GLP-1 Market Shift Affects Growth
Published: February 24, 2025 by: Seeking Alpha
Sentiment: Negative
Hims & Hers Health stock dropped 25% after the FDA announced the end of the semaglutide shortage, impacting Hims' weight loss services revenue. Hims plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide and tirzepatide. Despite the setback, Hims shows strong financial health with 77% Y/Y revenue growth and no long-term debt, warranting a "hold" recommendation.
Read More
Why Hims & Hers Health Stock Is Plummeting Today
Published: February 21, 2025 by: The Motley Fool
Sentiment: Negative
Shares of Hims & Hers Health (HIMS -24.30%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m.
Read More
Shares of Hims & Hers tumble 23% after FDA says semaglutide is no longer in shortage
Published: February 21, 2025 by: CNBC
Sentiment: Negative
The FDA announced on Friday that the shortage of semaglutide injection products like Novo Nordisk's Ozempic and Wegovy has been resolved. The FDA said Friday that it will start taking action against compounders for violations in the next 60 to 90 days.
Read More
Hims & Hers (HIMS) Down 21% – Is the GLP-1 Gravy Train Over?
Published: February 21, 2025 by: 24/7 Wall Street
Sentiment: Positive
“The Next NVIDIA” Could Change Your Life NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.
Read More
Hims and Hers Stock Drops Weight as Earnings Loom
Published: February 21, 2025 by: Schaeffers Research
Sentiment: Negative
Hims & Hers Health Inc (NYSE:HIMS) stock has had a roller coaster week.
Read More
Hims & Hers Health: The Ultimate Pick For The Next Decade
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. I provide multiple perspectives in this article, offering readers different viewpoints to draw their own conclusions. There are historical references, future valuations, and timeless investing lessons. There are five primary growth drivers that should continue to turbocharge HIMS' future revenue. I cover them all in detail.
Read More
Why Hims & Hers Stock Dropped Today
Published: February 20, 2025 by: The Motley Fool
Sentiment: Negative
Hims & Hers Health (HIMS -4.55%) tumbled 5.6% through 12:20 p.m. ET Thursday after Bank of America analysts gave mixed messages on the stock this morning.
Read More
Hims & Hers Stock Hits Record High on Blood-Testing Lab Acquisition
Published: February 19, 2025 by: Investopedia
Sentiment: Positive
Hims & Hers Health (HIMS) shares jumped roughly 20% to a fresh record high on Wednesday following the announcement that the company acquired lab testing facility Trybe Labs.
Read More
Why Hims & Hers Health Stock Is Skyrocketing Today
Published: February 19, 2025 by: The Motley Fool
Sentiment: Positive
Shares of Hims & Hers Health Inc (HIMS 20.27%) are flying higher on Wednesday. The company's stock gained 21.7% as of 2:00 p.m.
Read More
Hims & Hers to offer at-home blood draws and lab testing with new acquisition
Published: February 19, 2025 by: CNBC
Sentiment: Positive
Hims and Hers Health has acquired at-home lab testing facility Trybe Labs. The acquisition will allow the telehealth company to provide at-home lab testing through its platform.
Read More
Hims & Hers Acquires At-Home Lab Testing Facility, Expanding Capabilities to Ultimately Include Affordable Whole Body Testing for Subscribers
Published: February 19, 2025 by: Business Wire
Sentiment: Neutral
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc., the leading health and wellness platform, today announced its plans to introduce at-home lab testing through its platform. The new capability will empower customers to take control of their health with deeper insights and enable providers to access a breadth of data and biomarkers that can help identify risk of disease before it develops, for more precise clinical decision-making. The company has acquired an at-home lab testing facil.
Read More
Hims & Hers Q4 Preview: Is The Super Bowl Ad Worth $5B In Market Cap? (Rating Downgrade)
Published: February 18, 2025 by: Seeking Alpha
Sentiment: Neutral
Hims & Hers Health stock has surged 212% since my previous “buy” rating. Despite strong revenue and earnings growth expectations, I recommend holding off at the moment. Hims & Hers has consistently beat its revenue and earnings for the past several quarters, while the management has raised their forward expectations as a result of their Personalized solutions. However, the latest surge in the stock price is attributed to its provocative Super Bowl ad and favorable outlook on the regulatory landscape after RFK Jr.'s appointment as the Health Secretary.
Read More
Hims & Hers Earnings Could Be a Game Changer—What to Do Now
Published: February 18, 2025 by: MarketBeat
Sentiment: Positive
There are a few stocks that come along every once in a while, arriving to change the way an old-fashioned industry works and operates. When investors get lucky enough to find one of them, it can typically bring on life-changing returns, even retiring them from active work if they choose to go that route.
Read More
3 Hot Stocks That Have Already Doubled in 2025
Published: February 18, 2025 by: The Motley Fool
Sentiment: Positive
We're just a few weeks into 2025, but some stocks are already off to the races. There are already nine U.S. exchange-listed stocks with market caps north of $1 billion that have doubled this year.
Read More
Hims & Hers Stock Is On Fire, But Is It a Bubble?
Published: February 18, 2025 by: The Motley Fool
Sentiment: Positive
Shares of Hims & Hers (HIMS -0.96%) stock are up nearly 500% in the past year, but is the stock in bubble territory, or is there still growth ahead? Travis Hoium tackles that question plus the company's high short interest in this video.
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Household & Personal Products
- CEO Andrew Dudum
- Employees 1637